Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis
- PMID: 20062536
- PMCID: PMC2797635
- DOI: 10.1371/journal.pone.0008604
Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis
Abstract
BCL2 family members affect cell fate decisions in breast cancer but the role of BCL-W (BCL2L2) is unknown. We now show the integrated roles of the antiapoptotic BCL-W and BCL2 in affecting responsiveness to the antiestrogen ICI 182,780 (ICI; Fulvestrant Faslodex), using both molecular (siRNA; shRNA) and pharmacologic (YC137) approaches in three breast cancer variants; MCF-7/LCC1 (ICI sensitive), MCF-7/LCC9 (ICI resistant), and LY2 (ICI resistant). YC137 inhibits BCL-W and BCL2 and restores ICI sensitivity in resistant cells. Co-inhibition of BCL-W and BCL2 is both necessary and sufficient to restore sensitivity to ICI, and explains mechanistically the action of YC137. These data implicate functional cooperation and/or redundancy in signaling between BCL-W and BCL2, and suggest that broad BCL2 family member inhibitors will have greater therapeutic value than targeting only individual proteins. Whereas ICI sensitive MCF-7/LCC1 cells undergo increased apoptosis in response to ICI following BCL-W+/-BCL2 co-inhibition, the consequent resensitization of resistant MCF-7/LCC9 and LY2 cells reflects increases in autophagy (LC3 cleavage; p62/SQSTM1 expression) and necrosis but not apoptosis or cell cycle arrest. Thus, de novo sensitive cells and resensitized resistant cells die through different mechanisms. Following BCL-W+BCL2 co-inhibition, suppression of functional autophagy by 3-methyladenine or BECN1 shRNA reduces ICI-induced necrosis but restores the ability of resistant cells to die through apoptosis. These data demonstrate the plasticity of cell fate mechanisms in breast cancer cells in the context of antiestrogen responsiveness. Restoration of ICI sensitivity in resistant cells appears to occur through an increase in autophagy-associated necrosis. BCL-W, BCL2, and BECN1 integrate important functions in determining antiestrogen responsiveness, and the presence of functional autophagy may influence the balance between apoptosis and necrosis.
Conflict of interest statement
Figures






Similar articles
-
IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.Mol Cancer Ther. 2010 May;9(5):1274-85. doi: 10.1158/1535-7163.MCT-09-1169. Mol Cancer Ther. 2010. PMID: 20457620 Free PMC article.
-
Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.Clin Cancer Res. 2014 Jun 15;20(12):3222-32. doi: 10.1158/1078-0432.CCR-13-3227. Clin Cancer Res. 2014. PMID: 24928945 Free PMC article.
-
The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells.Mol Cancer Ther. 2005 Jan;4(1):33-41. Mol Cancer Ther. 2005. PMID: 15657351
-
AMBRA1, a Novel BH3-Like Protein: New Insights Into the AMBRA1-BCL2-Family Proteins Relationship.Int Rev Cell Mol Biol. 2017;330:85-113. doi: 10.1016/bs.ircmb.2016.09.002. Epub 2016 Nov 15. Int Rev Cell Mol Biol. 2017. PMID: 28215535 Review.
-
The role of Bcl‑2 in controlling the transition between autophagy and apoptosis (Review).Mol Med Rep. 2025 Jul;32(1):172. doi: 10.3892/mmr.2025.13537. Epub 2025 Apr 17. Mol Med Rep. 2025. PMID: 40242969 Free PMC article. Review.
Cited by
-
Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness.Cancer Res. 2012 Jul 1;72(13):3337-49. doi: 10.1158/0008-5472.CAN-12-0269. Cancer Res. 2012. PMID: 22752300 Free PMC article.
-
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy.Cells. 2023 Apr 14;12(8):1156. doi: 10.3390/cells12081156. Cells. 2023. PMID: 37190065 Free PMC article. Review.
-
miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets.Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3(0 3):273-97. doi: 10.1016/j.mce.2015.01.035. Epub 2015 Feb 3. Mol Cell Endocrinol. 2015. PMID: 25659536 Free PMC article. Review.
-
GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells.Mol Cancer Ther. 2013 Apr;12(4):448-59. doi: 10.1158/1535-7163.MCT-12-0617. Epub 2013 Feb 8. Mol Cancer Ther. 2013. PMID: 23395885 Free PMC article.
-
Antiestrogen Resistance and the Application of Systems Biology.Drug Discov Today Dis Mech. 2012;9(1-2):e11-e17. doi: 10.1016/j.ddmec.2012.10.003. Epub 2012 Dec 1. Drug Discov Today Dis Mech. 2012. PMID: 23539064 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
-
- Howell A, Robertson JF, Quaresma AJ, Aschermannova A, Mauriac L, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403. - PubMed
-
- Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–3395. - PubMed
-
- Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316–7339. - PubMed
-
- Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev. 2001;53:25–71. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials